US5961974A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
US7405270B2
(en)
*
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
US5474771A
(en)
|
1991-11-15 |
1995-12-12 |
The Trustees Of Columbia University In The City Of New York |
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
|
US7070777B1
(en)
|
1991-11-15 |
2006-07-04 |
The Trustees Of Columbia University In The City Of New York |
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
|
CA2089229C
(fr)
|
1992-02-14 |
2010-04-13 |
Alejandro A. Aruffo |
Recepteur cd40cr et ligands pour celui-ci
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
US6340459B1
(en)
|
1995-12-01 |
2002-01-22 |
The Trustees Of Columbia University In The City Of New York |
Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
|
ATE219376T1
(de)
*
|
1996-03-20 |
2002-07-15 |
Bristol Myers Squibb Co |
Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
|
KR20000070034A
(ko)
*
|
1997-01-10 |
2000-11-25 |
아스트루 마이클 제이 |
항 cd40l 화합물로 신염성 루푸스를 치료하는 방법
|
JP2001508450A
(ja)
*
|
1997-01-10 |
2001-06-26 |
バイオジェン インコーポレイテッド |
抗cd40l化合物の治療学的投与の方法
|
EP1754490A3
(fr)
|
1997-06-20 |
2010-01-20 |
Biogen Idec MA Inc. |
Thérapie de blocage par CD154 pour transplantation de tissus d'ilots pancréatiques chez les primates
|
AU8132998A
(en)
*
|
1997-06-20 |
1999-01-04 |
Tanox Pharma B.V. |
Anti-cd40l immunotoxins for the treatment of diseases
|
WO1999000143A1
(fr)
*
|
1997-06-27 |
1999-01-07 |
Biogen, Inc. |
Therapie de blocage par cd154 pour maladies auto-immunes
|
US7060667B1
(en)
|
1998-01-30 |
2006-06-13 |
Biogen Idec Ma, Inc. |
Treatment of follicular lymphomas using inhibitors of the LT pathway
|
HUP0101689A3
(en)
*
|
1998-04-03 |
2004-08-30 |
Trustees Of Darmouth College H |
Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
|
CA2345903C
(fr)
*
|
1998-10-16 |
2006-09-26 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. |
Pathogenicide moleculaire induisant une resistance a la maladie chez des vegetaux
|
US6927203B1
(en)
*
|
1999-08-17 |
2005-08-09 |
Purdue Research Foundation |
Treatment of metastatic disease
|
US7192698B1
(en)
*
|
1999-08-17 |
2007-03-20 |
Purdue Research Foundation |
EphA2 as a diagnostic target for metastatic cancer
|
FR2798386B1
(fr)
*
|
1999-09-10 |
2003-04-25 |
Didier Raoult |
Oligonucleotides monocatenaires, sondes, amorces et procede de detection des spirochetes
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
DE19962583A1
(de)
*
|
1999-12-23 |
2001-06-28 |
Mueller Hermelink Hans Konrad |
Antikörper gegen Plasmazellen
|
GB0006398D0
(en)
|
2000-03-16 |
2000-05-03 |
Novartis Ag |
Organic compounds
|
WO2001079555A2
(fr)
|
2000-04-14 |
2001-10-25 |
Millennium Pharmaceuticals, Inc. |
Roles des membres de la famille jak/stat dans l'induction de la tolerance
|
AU2001261585B2
(en)
|
2000-05-12 |
2006-08-31 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for achieving immune suppression
|
SK287940B6
(sk)
|
2000-07-03 |
2012-05-03 |
Bristol-Myers Squibb Company |
Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
DE60121346T8
(de)
*
|
2000-08-04 |
2007-12-13 |
Ludwig Institute For Cancer Research |
Suppressor-Gen
|
EP1314037A2
(fr)
*
|
2000-09-01 |
2003-05-28 |
Biogen, Inc. |
Procedes de designation et de produciton de nouveaux composes ayant une meilleure affinite de liaison pour cd154 ou d'autres proteines trimeriques
|
US7101976B1
(en)
|
2000-09-12 |
2006-09-05 |
Purdue Research Foundation |
EphA2 monoclonal antibodies and methods of making and using same
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
AU2008200400B2
(en)
*
|
2001-01-17 |
2012-06-07 |
Aptevo Research And Development Llc |
Binding domain-immunoglobulin fusion proteins
|
RU2420537C2
(ru)
*
|
2001-01-17 |
2011-06-10 |
Трабьон Фармасьютикалз Инк. |
Слитые белки связывающий домен-иммуноглобулин
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
JP4837880B2
(ja)
|
2001-05-23 |
2011-12-14 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ctla4突然変異体分子を使って同種異系島移植片を保護する方法
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
CN1678634A
(zh)
*
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
EP1831258B2
(fr)
*
|
2004-12-28 |
2023-06-07 |
Innate Pharma S.A. |
Anticorps monoclonaux contre le nkg2a
|
BRPI0610470A2
(pt)
|
2005-05-26 |
2010-06-22 |
Seattle Genetics Inc |
anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
|
EP1912675B1
(fr)
*
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
CN103272232B
(zh)
|
2006-06-08 |
2018-07-24 |
中外制药株式会社 |
炎性疾病的预防或治疗药
|
US8409577B2
(en)
*
|
2006-06-12 |
2013-04-02 |
Emergent Product Development Seattle, Llc |
Single chain multivalent binding proteins with effector function
|
EP2038306B1
(fr)
|
2006-06-30 |
2014-12-03 |
Novo Nordisk A/S |
Anticorps anti-nkg2a et leurs utilisations
|
US8338376B2
(en)
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
KR20090071652A
(ko)
|
2006-10-20 |
2009-07-01 |
바이오겐 아이덱 엠에이 인코포레이티드 |
가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
|
IL199534A
(en)
|
2007-01-05 |
2013-01-31 |
Univ Zuerich |
An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
|
PT2099826E
(pt)
*
|
2007-01-05 |
2014-01-09 |
Univ Zuerich |
Anticorpo anti-beta-amilóide e suas utilizações
|
SI2202245T1
(sl)
|
2007-09-26 |
2016-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
US20090124022A1
(en)
*
|
2007-10-19 |
2009-05-14 |
Abbott Laboratories |
Antibodies that bind to mammalian ngal and uses thereof
|
US8846036B2
(en)
*
|
2007-10-19 |
2014-09-30 |
Abbott Laboratories |
Antibodies that bind to mammalian NGAL and uses thereof
|
US20090123946A1
(en)
*
|
2007-10-19 |
2009-05-14 |
Abbott Laboratories |
Immunoassays and kits for the detection of ngal
|
KR101643005B1
(ko)
|
2007-12-05 |
2016-07-28 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
EP2241332A4
(fr)
|
2007-12-05 |
2011-01-26 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique contre le prurit
|
JP5774312B2
(ja)
|
2008-01-24 |
2015-09-09 |
ノボ・ノルデイスク・エー/エス |
ヒト化抗ヒトnkg2aモノクローナル抗体
|
JP6013733B2
(ja)
*
|
2008-04-11 |
2016-10-25 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
|
PL2275443T3
(pl)
|
2008-04-11 |
2016-05-31 |
Chugai Pharmaceutical Co Ltd |
Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
|
CA2730201C
(fr)
*
|
2008-07-10 |
2019-02-05 |
Toray Industries, Inc. |
Anticorps anti-cd179b
|
US20100124764A1
(en)
*
|
2008-09-26 |
2010-05-20 |
Wyeth |
Single chain antibody library design
|
EP2367849B1
(fr)
|
2008-12-05 |
2017-11-01 |
ALS Therapy Development Institute |
Méthode pour le traitement des maladies neurodegeneratives
|
JP5139517B2
(ja)
*
|
2008-12-05 |
2013-02-06 |
中外製薬株式会社 |
抗nr10抗体、およびその利用
|
KR20160062207A
(ko)
*
|
2008-12-05 |
2016-06-01 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
JP2010210772A
(ja)
*
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region change body
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
MX365235B
(es)
|
2010-11-30 |
2019-05-28 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
|
US9783594B2
(en)
|
2011-05-17 |
2017-10-10 |
The Rockefeller University |
Human immunodeficiency virus neutralizing antibodies and methods of use thereof
|
BR112013032217B1
(pt)
|
2011-06-17 |
2021-01-19 |
Novo Nordisk A/S |
uso de um anticorpo anti-nkg2a
|
WO2013012733A1
(fr)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
|
EA030852B1
(ru)
|
2011-10-13 |
2018-10-31 |
Бристол-Майерс Сквибб Компани |
Полипептиды антител, которые вызывают антагонизм cd40l
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
MX2017013141A
(es)
|
2015-04-14 |
2018-02-21 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
|
KR20180053322A
(ko)
|
2015-09-21 |
2018-05-21 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
EP3565596A4
(fr)
|
2017-01-05 |
2020-12-16 |
Brown University |
Procédés et compositions se rapportant à des réactifs de type anticorps anti-chi3li
|
PT3672631T
(pt)
|
2017-08-22 |
2023-05-23 |
Biogen Ma Inc |
Composições farmacêuticas contendo anticorpos anti-betaamiloide
|
US10766968B2
(en)
|
2017-08-23 |
2020-09-08 |
Brown University |
Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
|
CN108484761B
(zh)
*
|
2018-03-10 |
2021-04-30 |
吉林大学 |
一种特异性识别并诱导Aβ42的寡聚体及原纤维解聚的单链抗体、单链抗体基因及其应用
|
CN110950953B
(zh)
*
|
2018-09-26 |
2022-05-13 |
福州拓新天成生物科技有限公司 |
抗b7-h3的单克隆抗体及其在细胞治疗中的应用
|
KR102142499B1
(ko)
*
|
2019-09-11 |
2020-08-10 |
재단법인 오송첨단의료산업진흥재단 |
Ykl-40 표적 인간 단일클론항체
|
JP6845973B1
(ja)
|
2019-11-20 |
2021-03-24 |
中外製薬株式会社 |
抗体含有製剤
|